Paul Daniel Iordache

Paul Daniel Iordache

Clinical-Therapeutic Correlations in Patients with Iron Deficiency and Helicobacter Pylori Infection

Helicobacter pylori (H.pylori) infection is among the most common infections found in the human population. It is acquired during childhood and persists whole life if not treated. It is commonly found in the elderly, disadvantaged persons, people in general with poor socio-economic status. H.pylori infection may associate iron deficiency due to defective iron take-over from the diet. The objective of this study, on the causal relationship between H.pylori infection and iron deficiency with/without anaemia, was the evaluation of haematological parameters (haemoglobin, haematocrit, mean corpuscular volume, sideraemia, ferritin) in patients diagnosed with active H.pylori infection and iron deficiency. Out of 681 patients admitted during a period of 5 years in the Focşani Military Hospital with active H.pylori infection, 9.4% (64 patients) presented iron deficiency with/without anaemia, as a cause of H.pylori infection. Of these, 12 patients (18.75%) have normalized their hematological parameters 3 months after triple therapy. Another 25 patients (39.07%) with iron supplements associated, responded favorably to 6 months, more pronounced than the control group of 27 patients (42.18%) who received only iron preparations without triple therapy. The study highlights the need to investigate H.pylori infection in patients with iron deficiency with/without anemia. In this situation, eradication therapy is required.

Read More »

Genome-Wide Association Scan for Variants Associated with Early-Onset Prostate Cancer in Romania

Prostate cancer incidence varies more than 25-fold worldwide, largely due to the widespread practice of prostate specific antigen (PSA) testing and subsequent biopsy [1]. It is the second most frequently diagnosed cancer of men (914.000 new cases per year, accounting for 13.8% of total cancer cases) and the 5th most common cancer overall worldwide. The incidence is expected to grow to 1.7 million new cases and 499.000 deaths by 2030, mainly due to the growth and aging of the global population [2]. [...]

Read More »
Skip to content